Equity Research Medical Care Facilities

Should You Buy DocGo Inc. Stock in 2026?

By CirclFi Research Team · · Updated · 4/13 models active

According to the CirclFi Deep Alpha Valuation Engine, DocGo Inc. (DCGO) carries a solid Quality of Company rating of 6.8/10. Trading at $0.38, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.

The short answer: 3 of 4 CirclFi valuation models project upside for DocGo Inc. (DCGO) at $0.38 — the model consensus leans bullish, with a Quality Score of 6.8/10 and Value-Trap risk of 37/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 3 of 4 models see upside — majority bullish
  • Quality Score: 6.8/10 — Moderate — mixed signals
  • Value Trap Risk: 37/100 — Low — manageable risk
  • Fair Value Range: $0.15 – $2.10 (1282% spread)

Bullish Models

3 / 4

Bearish Models

1 / 4

Quality Score

6.8 /10

Moderate — mixed signals

Value Trap Risk

37 /100
Low

Low — manageable risk

Model Consensus

4 /13
Active Models

Avg. confidence: 40%

What Is the Investment Case for DocGo Inc. (DCGO) in 2026?

What Is the Bull Case vs the Bear Case for DocGo Inc. (DCGO)?

Bull case versus bear case for DocGo Inc. (DCGO) at $0.38, derived from 4 active CirclFi valuation models on 2026-09-15.
Bull case — $2.10 target (+444.7%) Bear case — $0.15 target (-60.6%)
According to the CirclFi Deep Alpha Valuation Engine, 3 of 4 models identify upside from $0.38 to a median fair value of $1.43, indicating the market hasn't fully priced in DocGo Inc.'s earnings power. According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model sees the stock as overvalued with a fair value of $0.15 (-60.6%), suggesting that the market price embeds overly optimistic growth assumptions.
According to the CirclFi Deep Alpha Valuation Engine, the CUCE model targets a fair value of $2.10 (+444.7%), anchoring the bull case with a methodology that provides a differentiated analytical lens. According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +505.3% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.

How Does DCGO Compare to Its Medical Care Facilities Peers?

CYH Community Health Sys
7.1
INNV InnovAge Holding Cor
6.8
ASTH Astrana Health, Inc.
7.1
AMN AMN Healthcare Servi
6.7
AUNA Auna SA
7.2
CCEL Cryo-Cell Internatio
6.7
BKD Brookdale Senior Liv
5.7
GMRS GMR Solutions Inc.
3.8

Valuation data pages: CYH · INNV · ASTH · AMN · AUNA · CCEL · BKD · GMRS · USPH · ADUS · NHC

See full Medical Care Facilities rankings →

Which Other Stocks Score Like DCGO on Quality?

Closest companies to DCGO’s Quality of Company score of 6.8/10, across all industries.

Why Do CirclFi’s 4 Models Disagree on DCGO?

Spread

1282%

Fair Value Range

$0.15 – $2.10

A 1282% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

CUCE

$2.10 (+444.7%)

Most Bearish

Dynamic NAV

$0.15 (-60.6%)

What Are the Biggest Risks of Buying DCGO Stock?

Model Disagreement

1282% spread signals high variance in projections.

Macro/Sector Risk

Medical Care Facilities headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View DCGO Data Page →

So Is DocGo Inc. (DCGO) Worth Buying in 2026?

DocGo Inc. at $0.38 presents what our engine identifies as a high-conviction opportunity: 3 of 4 models see upside, quality stands at 6.8/10, and the median fair value of $1.43 implies +271.2% return potential. Investors should verify this thesis against their own risk parameters and time horizon.

These are quantitative model outputs, not investment recommendations. DocGo Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About DCGO Stock?

Should I buy DCGO stock right now?

Based on CirclFi's multi-model analysis, 3 of 4 models see upside for DCGO at $0.38. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 6.8/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in DocGo Inc.?

Key risks include: limited model coverage (4/13 active), reducing analytical confidence; wide model disagreement (1282% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Care Facilities companies. Always diversify and consult a financial advisor.

How does DCGO compare to its competitors?

Among Medical Care Facilities peers, DCGO holds a Quality Score of 6.8/10. Comparable companies include CYH (QOC 7.1), INNV (QOC 6.8), ASTH (QOC 7.1). The relative ranking helps investors identify whether DCGO offers better fundamental quality than alternatives in the same sector.

Is DCGO a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. DCGO's Quality Score of 6.8/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy DCGO at?

CirclFi does not provide target buy prices or price alerts. However, our 4 active models produce fair value estimates ranging from $0.15 to $2.10. At $0.38, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for DCGO.

View DCGO Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →